Diligence memo · auto-generated · as of July 2, 2026
Monitored Therapeutics, Inc.
Monitored Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Monitored Therapeutics, Inc. operates in Pharma, based in DUBLIN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Monitored Therapeutics, Inc. has raised $8.5M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.3M on 2021-07-21.
Most recent recorded round closed around 2021-07-21.
Valuation (modeled)modeled
Provath models Monitored Therapeutics, Inc. at approximately $82M (range $4.9M–$352M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.43× the median modeled value of Series A Pharma companies in 2019–2021 (24 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 23 months.
Last raise 4.9 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 63% of Pharma peers (310 compared).
Modeled value ranks above 64% of those peers.
Closest niche peers: Comet Therapeutics, Inc., RadImmune Therapeutics, Inc., Nanoscope Therapeutics, Inc., ZebiAI Therapeutics, Inc., Blue Note Therapeutics, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.